Clinical trials: Venous Thrombosis (Disorder)
Venous Thromboembolism, Deep Vein Thrombosis
OsciPulse Device for the Prevention of VTE
This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
- Trial name
- NCT04625673
- Testing
- OsciPulse
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
DVT - Deep Vein Thrombosis, POCUS
Clinical Application of Wearable Ultrasound Sensors
This study aims to develop and evaluate a wearable ultrasound imaging sensor for the early diagnosis and real-time monitoring of various diseases, such as cardiovascular conditions and structural abnormalities of superficial…
- Trial name
- NCT07009873
- Testing
- This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Myeloma, Venous Thromboembolism
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an…
- Trial name
- MYELAXAT (NCT02066454)
- Testing
- Apixaban
- Where
- 19 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Grenoble
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Venous Thromboembolism
Development and Validation of the Patient-completed Caprini Risk Score
The investigators aimed to test the reliability and validity of the Chinese version of patient-completed CRS in hospitalized patients and to evaluate whether this form can be widely used in clinical practice instead of only…
- Trial name
- NCT04663477
- Testing
- patient-completed Caprini Risk Score
- Where
- China
- Volunteers
- 1,017 people, healthy volunteers welcome
- Sponsor
- China-Japan Friendship Hospital
Deep Vein Thrombosis
Full-Leg vs Below-Knee Elastic Stockings for Prevention of the Post-Thrombotic Syndrome
Prospective controlled randomized clinical trial. Consecutive patients with acute proximal deep vein thrombosis of the lower extremities, with or without contemporary manifestations of pulmonary embolism, are randomized to…
- Trial name
- NCT00426075
- Testing
- Elastic stockings
- Where
- Italy
- Sponsor
- University of Padova
Venous Thromboembolism, Fetal Death
Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)
The purpose of this study is to determine the risk of fetal loss in women with unprovoked venous thromboembolism (VTE) who do not have identifiable inherited thrombophilia compared with women who have the diagnosis of venous…
- Trial name
- NCT00149357
- Testing
- Thrombophilia Testing
- Where
- 5 sites in Australia, Canada
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- McMaster University
Retinal Vein Occlusion
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S.
- Trial name
- NCT00088283
- Testing
- pegaptanib sodium
- Where
- 35 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eyetech Pharmaceuticals
Hepatocellular Carcinoma, Portal Vein Thrombosis
Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring
The goal of this multicenter retrospective cohort study is to investigate the clinical outcomes and prognostic factors after hepatic resection in patients with HCC exhibiting PVTT, and to develop a prognostic index that can be…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Thrombosis, Prognosis
- Trial name
- NCT06005883
- Where
- South Korea
- Volunteers
- 332 people
- Sponsor
- Keimyung University Dongsan Medical Center
Venous Thromboembolism
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
- Trial name
- NCT02464969
- Testing
- Apixaban, Standard of Care
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Deep Vein Thrombosis of the Lower Extremities
AI-Based Prediction Model for Iliofemoral DVT Thrombolysis
This prospective single-arm cohort study aims to develop an AI-powered prediction model for treatment outcomes in patients with acute extensive iliofemoral deep vein thrombosis (IF-DVT) undergoing stent-free pharmacomechanical…
- Trial name
- NCT07181083
- Testing
- Rheolytic thrombectomy
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Thromboembolism
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks.
- Trial name
- EXTEND (NCT00206089)
- Testing
- EXANTA
- Where
- 125 sites in Austria, Belgium and 14 more
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Branch Retinal Vein Occlusion
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- NCT04667897
- Testing
- 601 1.25mg, Ranibizuman 0.5 mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Cirrhosis, Splenectomy; Status
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy
- Conditions
- Cirrhosis, Splenectomy; Status, Venous Thrombosis, Hypertension, Portal
- Trial name
- NCT04645550
- Testing
- Apixaban, Warfarin, Aspirin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Northern Jiangsu People's Hospital
Central Venous Catheter Thrombosis, Central Venous Catheter Related Bloodstream Infection
CLiCK in the Critical Care Unit
Insertion of a central venous access device (CVAD) allows clinicians to easily access the circulation of a patient to administer life-saving interventions.
- Conditions
- Central Venous Catheter Thrombosis, Central Venous Catheter Related Bloodstream Infection, Catheter Complications, Catheter Blockage
- Trial name
- CLiCK (NCT04548713)
- Testing
- 4% EDTA, Saline
- Where
- 6 sites in Canada
- Volunteers
- 1,449 people
- Sponsor
- Fraser Health
Deep Venous Thrombosis, Pulmonary Embolism
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
- Trial name
- NCT04583878
- Testing
- Blood draw (Visit 1), Blood draw (Visits 2 and 3)
- Where
- 14 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Venous Thromboembolism
Electronic Strategies to Enhance Venous Thromboemboli (VTE) Prophylaxis in Hospitalized Medical Patients
Venous thromboemboli (VTE) are abnormal blood clots that commonly form in the blood vessels of the legs or lungs. They can block normal blood flow, damage organs, and even cause death.
- Trial name
- E-SENTRY (NCT01401725)
- Testing
- Electronic Order Entry System + CDSS, Electronic Order Entry System Only, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Urologic Cancer, Thrombosis
Thrombembolism After Robot- Assisted Surgery in Urology
Cancer patients have an increased risk of perioperative complications undergoing surgery procedures. Postoperative complications caused by thrombembolic events after robot- assisted surgery in major urological procedures have…
- Conditions
- Urologic Cancer, Thrombosis, Embolism, Surgery--Complications
- Trial name
- NCT04796740
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- University Hospital Schleswig-Holstein
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch…
- Trial name
- BRAVO (NCT00486018)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 397 people
- Sponsor
- Genentech, Inc.